

250
200
150
100
50
0
Telomerase Products per cell equivalent
*= Statistically significant compared to Untreated (p<0.01)
*
*
Stem Cells
EC376
EC376 + Sec ID 1
EC382
EC382 + Sec ID 1

FIG. 1




90
80
70
60
50
40
30
20
10
0
Telomere Length (kb per diploid genome)
*= Statistically significant compared to Untreated (p<0.01)
*
*
Stem Cells
EC376
EC376 + Sec ID 1
EC382
EC382 + Sec ID 1

FIG. 2



SEQ ID 1 administered PO at 200 µg/day
Peripheral blood draws taken pre-dose and 90 days post dose

FIG. 3



14000
12000
10000
8000
6000
4000
2000
0
Telomere Length (BP)
Pre
Post
1
2
3
4
5
6
7
8

FIG. 4



SEQ ID 1 Increases Telomere Length in 6/8 Patients
Pre
Post
14000
12000
10000
8000
6000
4000
2000
0
Telomere Length (BP)
1
2
3
4
5
6
7
8
Average
*
Patient
*= p < 0.05

FIG. 5



SEQ ID 1 Increases Telomere Length in 6/6 Patients
Pre
Post
Telomere Length (BP)
9000
8800
8600
8400
8200
8000
7800
7600
7400
7200
PT1
PT3
PT4
PT6
PT7
PT9
Average
*
*= p < 0.05

FIG. 6



Cholesterol
215.0
210.0
205.0
200.0
195.0
190.0
185.0
180.0
Pre
Post
Triglycerides
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
Pre
Post
LDL-Cholesterol
140.0
135.0
130.0
125.0
120.0
115.0
110.0
105.0
Pre
Post
HS-CRP
2.5
2.0
1.5
1.0
0.5
0.0
Pre
Post
Glucose
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
*
Pre
Post
HgA1C
6.4
6.2
6.0
5.8
5.6
5.4
5.2
5.0
4.8
Pre
Post
*= p < 0.05

FIG. 7



Alkaline Phosphatase
72.0
70.0
68.0
66.0
64.0
62.0
60.0
58.0
56.0
Pre
Post
ALT
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Pre
Post
AST
25.0
20.0
15.0
10.0
5.0
0.0
Pre
Post
Bilirubin
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pre
Post
BUN
19.0
18.5
18.0
17.5
17.0
16.5
16.0
15.5
15.0
Pre
Post
Creatinine
1.0
1.0
1.0
1.0
0.9
0.9
0.9
0.9
0.8
0.8
Pre
Post

FIG. 8



SEQ ID 1 Increases Relative Telomerase Activity in 6/6 Patients
PreRTA
PostRTA
Relative Telomerase Activity (RTA)
1.4
1.2
1
0.8
0.6
0.4
0.2
0
PT1
PT3
PT4
PT6
PT7
PT9
Average

FIG. 9